SMi Presents the 13th Annual 20 - 21 Pain Therapeutics M A Y Copthorne Tara Hotel, London, UK 2013 WHY ATTEND THIS EVENT: FEATURED SPEAKERS: • Balance of clinical and pre-clinical considerations • Dave Shelton, Executive Director Pfizer , alongside therapeutic applications • Narender Gavva, Scientific Director Amgen , • Focus on personalised medicine and translational • Stephen Arneric, Senior Research Fellow, Eli Lilly methods aiming to develop the efficacy of drugs • Thomas Christoph, Global Preclinical Research and • Explore the use of anti-NGFs in the treatment of Development, Grunenthal pain alongside the discovery of novel targets • Huw Rees, Senior Principal Scientist, Pfizer • Spotlight on translational mechanistic pain • Steve Harrison, Vice President, Research Biology, biomarkers Nektar Therapeutics • Study the use of imaging modalities such as fMRI • Iain Chessell, Head, Neuroscience Centre of Excellence, for pain measurement MedImmune • Network with key industry professionals and • Valerie Morisset, Head of Electrophysiology, discuss the future of pain therapeutics Convergence Pharmaceuticals PLUS TWO INTERACTIVE POST-CONFERENCE WORKSHOPS 22ND MAY 2013 | COPTHORNE TARA HOTEL | LONDON, UK Workshop A: Workshop B: Human Pain Models - Lost in Translation? Using phenotyping and imaging to improve early 08.30 – 12.30 drug development and clinical trial designWorkshop Leaders: Jonathan Stewart, Consultant, Pain Medicine, 13.30 – 17.30 Imperial NHS Trust, London Workshop Leader: Anthony Jones, Professor of Zahid Ali, Senior Director, Pfizer Neuro-rheumatology, University of Manchester Remigiusz Lecybyl, Consultant in Chronic Pain, Lewisham Hospital To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737, email firstname.lastname@example.org or visit www.smi-online.co.uk/ts07.asp to register online
DAY ONE | 20TH MAY 2013 Pain Therapeutics08.30 REGISTRATION & COFFEE 12.10 Chronic pain treatments tailored for the elderly: are we prepared for the approaching tsunami? • Chronic pain is becoming increasingly recognized as a disease -09.00 CHAIRMAN’S OPENING REMARKS: accounts for substantial suffering and disability world-wide Dave Shelton, Executive Director, Pfizer • The aging “Baby-boomer” generation • The phenotypic expression of chronic pain in the elderly • A paradigm shift in the drug discovery paradigm PERSONALISED MEDICINE & ANIMAL MODELS Stephen Arneric, Senior Research Fellow, Eli Lilly 12.50 NETWORKING LUNCH09.10 The use of ddRNA interference as a gene therapy approach to cancer pain management CURRENT & NOVEL TARGETS • Inflammation and epigenetics - developing treatments • Understanding the epigenome - combination therapy 14.10 The use of anti-NGF agents in pain • Application of epigenetics to answer questions about • Novel approach to treating pain established drugs • anti-NGF in clinical trials Peter French, Chief Executive Officer, Benitec Biopharma • Challenges faced • Future of anti-NGF agents Dave Shelton, Executive Director, Pfizer09.50 Novel readouts for the analysis of spontaneous pain in animals 14.50 Novel pain therapeutics with low CNS side effects • How do evoked methods compare with non-evoked? • Use of polymer conjugation technology to develop novel • Are innate responses of animals suitable measures for opioids with intrinsically low abuse liability chronic pain? • Analgesics for neuropathic pain with reduced CNS side effects • Are different pain indications amenable to similar readouts? • The future potential of polymer conjugation technology in Thomas Christoph, Global Preclinical Research and pain therapy Development, Grunenthal Steve Harrison, Vice President, Research Biology, Nektar Pharmaceuticals10.30 Optimising the context of medical treatments for 15.30 AFTERNOON TEA arthritis pain • The context within which treatments are given 15.50 Novel targets in inflammatory and neuropathic pain • Placebos and nocebo • Inflammatory and neuropathic pain poorly treated by • The place of medical analgesia in patient pathways for current analgesics – poor efficacy and many side effects chronic arthritis pain. • Recent work in the McNaughton lab has identified the HCN2 • The person-specific context; mechanistic, diagnostic and ion channel and the AKAP79 scaffolding protein as potential targets severity-based approaches to stratified care • Progress towards developing selective drugs David Walsh, Director of the ARC National Pain Centre, Peter McNaughton, Head of Pharmacology Department, University of Nottingham Cambridge University11.10 MORNING COFFEE 16.30 The use of biologic therapies in the treatment of pain - A CASE STUDY of anti-NGFs11.30 Exploring the use of animal models to study pain pathways • Why consider biologic therapies for pain: pros and cons • Mechanistic studies; examining the role of NaV1.7 in rats • Considerations around target selection • Case study: anti-NGF therapies and mice • Translation from man to animal to man • Addressing bias in preclinical studies; being more clinical in • Next steps for novel biologic therapies experimental design Iain Chessell, VP R&D, Neuroscience Innovative Medicines, • Future directions; re-evaluating the role of wide dynamic MedImmune range neurones in models of nerve injury Huw Rees, Senior Principal Scientist, Pfizer 17.10 Chairman’s Closing Remarks and Close of Day One To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737 email email@example.com or visit www.smi-online.co.uk/ts07.asp to register onlineWHO SHOULD ATTEND: Want to know how youHeads of Department, Directors, Managers, can get involved? Interested in promotingTeam Leaders Researchers and Scientists from: your pharmaceutical• Pain and inflammation target discovery • Chronic and neuropathic pain services to this market?• Analgesic preclinical development • Clinical trial design Contact Margaret Mugema,• CNS clinical trials • Biomarker development SMi Marketing on• Translational imaging • Personalised medicine +44 (0) 207 827 6072,• Early phase CNS research • Pain management or email• Epigenetics in pain and inflammation firstname.lastname@example.org Supported by
DAY TWO | 21ST MAY 2013 Pain Therapeutics08.30 REGISTRATION & COFFEE CLINICAL TRIAL MODELS & OVERCOMING CHALLENGES 11.40 Challenges in analgesic drug discovery09.00 CHAIRMAN’S OPENING REMARKS: • Emphasis is on preclinical discovery Narender Gavva, Scientific Director, Amgen • Potential false-positive hotspots • Best practices for target selection criteria EXPERIMENTAL MODELS Narender Gavva, Scientific Director, Amgen09.10 Translational mechanistic pain biomarkers 12.20 NETWORKING LUNCH • Phase I and II proof-of-concept 13.40 PFIZER SESSION – Current considerations in sodium • Pharmacodynamics &Mechanism based drug profiling channel blockers for pain management • Healthy volunteer studies Session 1: The discovery and preclinical development • Proof-of-mechanism of selective sodium channel blockers • Translation of animal data into pain patients • Strategies for gaining true selectivity in sodium channel Lars Arendt-Nielsen, Director, Center for Sensory-Motor blockers • Preclinical in vitro and in vivo profile of selective Nav 1.7 Interaction, Aalborg University blockers • Key criteria in clinical compound selection09.50 Human tissues as a translational tool in pain research Richard Butt, Director, Research Project Leader, Pfizer and target identification • Studies of neuropathic pain Session 2: Subtype selective sodium channel blockers • Studies of inflammatory pain • Functional properties • Novel classes of blockers • Correlation with pre-clinical models • The future of subtype selective sodium channel blockers Fiona Boissonade, Head of Neuroscience Research Group, Zahid Ali, Senior Director, Pfizer University Of Sheffield 15.00 Afternoon Tea10.30 MORNING COFFEE 15.30 CASE STUDY: Focus on Nav1.7 blockers for chronic pain • Preclinical and clinical programmes at Convergence11.00 Imaging the common brain substrates of chronic pain- Pharmaceuticals it’s all anticipation • Nav1.7 blockers - research findings and major conclusions • Recent research to suggest that fundamental changes in • The future of Nav1.7 blockers for chronic pain physiology of chronic pain sufferers may alter their PD Valerie Morisset, Head of Electrophysiology, Convergence compared to experimental models of healthy patients Pharmaceuticals • Can this research help to illuminate better ways at predicting 16.10 Panel discussion : Pain therapeutics, where are we and drug PD in patients? what is the potential for the future? • How do these physiological changes relate to pain? Panellists: Day 2 Speakers Anthony Kenneth Peter Jones, Professor of Neuro- Rheumatology, University of Manchester 16.50 Chairman’s Closing Remarks and Close of Day Two To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737 email email@example.com or visit www.smi-online.co.uk/ts07.asp to register onlineSMi PHARMACEUTICALS FORWARD PLANNER 2013FEBRUARY Imaging in Cancer Drug Pharmaceutical JUNE SPONSORSHIP AND Development Portfolio & LifecycleParallel Trade 13 – 14 March 2013, Management RNAi & Nanotechnology EXHIBITION OPPORTUNITIES6 – 7 February 2013, 5 – 6 June 2013, London London 17 – 18 April 2013,London London SMi offer sponsorship, Biobanking Controlled ReleaseAdvances and Progress 18 – 19 March 2013, MAY 24-25 June 2013, London exhibition, advertising andin Drug Design branding packages, uniquely London18 – 19 February 2013, Generics, Supergenerics AllergiesLondon & Patent Strategies 26 – 27 June 2013, tailored to complement your Paediatric Clinical Trials 13 – 14 May 2013, London London companys marketing strategy. 20 – 21 March 2013,Lyophilisation London Should you wish to join the- Freeze Drying in Pain Therapeutics ADMETPharmaceuticals 20 – 21 May 2013, London 26 – 27 June 2013, increasing number of APRILand Biopharmaceuticals London companies benefiting from25 – 26 February 2013, Adaptive Designs ADC SummitLondon 8 – 9 April 2013, London 20 – 21 May 2013, London JULY sponsoring our conferences Pharmacovigilance please call:MARCH Asthma & COPD Clinical Trial Logistics 1 – 2 July 2013, London Anuja Raut, SMi Sponsorship 15 – 16 April 2013, 22 – 23 May 2013, LondonSuperbugs & London on +44 20 7827 6128 orSuperdrugs - A Focus Cell Cultureon Antibacterials 3 – 4 July 2013, London email: firstname.lastname@example.org – 5 March 2013, London
INTERACTIVE POST CONFERENCE WORKSHOP A 22ND MAY 2013Human Pain Models - Lost in Translation? 08.30 – 12.30 Workshop Leaders: Jonathan Stewart, Consultant, Pain Medicine, Imperial NHS Trust, London Zahid Ali, Senior Director, Pfizer Remigiusz Lecybyl, Consultant in Chronic Pain, Lewisham HospitalOverviewThis workshop will be a uniquely interactivesession where attendees can explore currentlyused human pain models and theirtranslatability into the clinic. Led by theexperience of Jonathan Stewart, ImperialNHS Trust, London alongside the expertise ofZahid Ali, Pfizer and Remigiusz Lecybyl,Lewisham Hospital, the workshop aims tofacilitate the understanding of unmet needs inhuman pain modeling and successful translationto the clinic.Benefits of Attending• Address and overcome challenges associated with human pain models• Debate the attributes of currently used human pain models• Learn how successful models translate• Network with key professionals with considerable expertise in pain researchAgenda08.30 Registration & Coffee09.00 Introduction and Workshop Objectives09.10 Attributes of currently used models and which is best • Comparative models • Which model comes out on top09.45 Do experimental models really serve the function that they are intended for? • Functionality of human pain models • Major findings10.45 Morning Break11.00 How well do these experimental models translate? • Translation into the clinic12.10 Interactive Discussion12.30 Summary & close of workshopAbout Workshop Host:Dr Jonathan Stewart is an anaesthetist with almost 20 years clinical and research experience in pain. He has undertaken Consultant positions in pain management at Kings College, StMarys Hospital and Charing Cross Hospital,London as well as having an Honorary SeniorLecturer appointment at Imperial College,London.Dr Stewarts interests are in neuropathic pain,chronic spinal pain, musculoskeletal pain andfibromyalgia. He has led research teams in allthese areas, been an invited speaker at nationaland international conferences and advised theUK government as an invitee on the ChronicPain Policy Coalition.
INTERACTIVE POST CONFERENCE WORKSHOP B 22ND MAY 2013 Using phenotyping and imaging to improve early drug development and clinical trial design 13.30 – 17.30 Workshop Leader: Anthony Jones, Professor of Neuro-rheumatology, University of ManchesterOverviewThis workshop will be a uniquely interactive sessionwhere attendees can address and evaluate the useof phenotyping and imaging modalities to improvethe success of early drug development and clinicaltrial design. Led by the expertise of AnthonyJones, Professor of Neuro-rheumatology,University of Manchester, this workshop aims toprovide attendees with an exclusive insight intosuccessful methods that have improved drugdevelopment in pain, alongside discussing thefuture of pain therapeutics.Benefits of Attending• Address and overcome challenges associated with drug development in pain alongside clinical trial design• Discuss advances in patient phenotyping and ways to move forward with ones own research• Evaluate successful imaging modalities for early drug development• Network with key professionals with considerable expertise in pain researchAgenda13.30 Registration & Coffee14.00 Introduction and Workshop Objectives14.10 Using imaging modalities in drug design • Recent PET studies • Successful imaging modalities14.45 Application of patient phenotyping • Drug development via phenotyping • Patient phenotyping and clinical trial design15.45 Morning Break16.00 Early drug development and clinical trial design • Current applications of phenotyping alongside imaging • Major findings and conclusions17.10 Interactive Discussion17.30 Summary & close of workshopAbout Workshop Host:Anthony Jones is professor of Neuro-rheumatology at Manchester University andleads the Human Pain Research Group. Whilst atthe Hammersmith Hospital he pioneered thedevelopment of techniques to imageneurochemical and metabolic brain responses topain using Positron Emission Tomography. Over SPONSORSHIP ANDthe last twenty years he has used a number offunctional brain imaging techniques to EXHIBITIONunderstand that the normal and abnormalmechanismsOPPORTUNITIES of pain perception.There is offer the exciting prospect of using SMi now sponsorship, exhibition,some of the insights gained in these studies to advertising and branding packages,develop new approaches to complement uniquely tailored to pharmacologicaland cognitive interventions for chronic pain. He your companys marketing strategy.also leads the International Association of PainMusculoskletal Pain Taskforce to join the the Should you wish and is leadingdevelopment of number of companies increasing National and InternationalGuidelines on the from sponsoring our of benefiting Integrated ManagementMusculoskeletal Pain (jointly sponsored by the conferences please call: Anuja Raut,BSR and the IASP). SMi Sponsorship on +44 20 7827 6128
PAIN THERAPEUTICSConference: Monday 20th and Tuesday 21th May 2013, Copthorne Tara Hotel, London, UK Workshops: Wednesday 22nd May 2013, London 4 WAYS TO REGISTER ONLINE at www.smi-online.co.uk/ts07.asp FAX your booking form to +44 (0) 20 7827 6737 POST your booking form to: Cem Tuna, SMi Group Ltd, 2nd Floor South, PHONE on +44 (0) 20 7827 6736 Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD □ Book by 28th February to receive a £300 off the conference price DISCOUNT □ Book by 28th March to receive a £100 off the conference price CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference & 2 Workshops £2697.00 + VAT £3236.40 □ Conference & 1 Workshop £2098.00 + VAT £2517.60 □ Conference only £1499.00 + VAT £1798.80 Unique Reference Number □ 1 Workshop only £599.00 + VAT £718.80 Our Reference LVP-067 ts □ 2 Workshops £1198.00 + VAT £1437.60 Workshop A □ Workshop B □ DELEGATE DETAILS PROMOTIONAL LITERATURE DISTRIBUTION Please complete fully and clearly in capital letters. Please photocopy for additional delegates. □ Distribution of your company’s promotional Title: Forename: literature to all conference attendees £999.00 + VAT £1198.80 Surname: Job Title: The conference fee includes refreshments, lunch, conference papers and access Department/Division: to the Document Portal containing all of the presentations. Company/Organisation: Email: VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR Company VAT Number: Address: □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: email@example.com or fax +44 (0) 870 9090 712 Town/City: Post/Zip Code: Country: DOCUMENTATION Direct Tel: Direct Fax: I cannot attend but would like to purchase access to the following Document Mobile: Portal/paper copy documentation Price Total Switchboard: □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 Signature: Date: □ The Conference Presentations – paper copy £499.00 - £499.00 I agree to be bound by SMis Terms and Conditions of Booking. (or only £300 if ordered with the Document Portal) ACCOUNTS DEPT Title: Forename: PAYMENT Surname: Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-067 and the delegate’s name. Bookings Email: made within 7 days of the event require payment on booking, methods of payment Address (if different from above): are below. Please indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Town/City: Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 Post/Zip Code: Country: □ Cheque We can only accept Sterling cheques drawn on a UK bank. Direct Tel: Direct Fax: □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. Terms and Conditions of Booking Card No: □□□□ □□□□ □□□□ □□□□ Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may Cardholder’s Name: not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a Signature: Date: substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing I agree to be bound by SMis Terms and Conditions of Booking. that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable Card Billing Address (If different from above): to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other VAT products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document that we hold then please contact our Database Manager firstname.lastname@example.org or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on Portal and Literature Distribution for all UK customers and for those EU customers not supplying the attached letter. a registration number for their own country here: ______________________________________ If you have NOT received registration confirmation within 48 hours of registering, please call +44 (0) 20 7827 6736